![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CMPK2 |
Gene summary for CMPK2 |
![]() |
Gene information | Species | Human | Gene symbol | CMPK2 | Gene ID | 129607 |
Gene name | cytidine/uridine monophosphate kinase 2 | |
Gene Alias | NDK | |
Cytomap | 2p25.2 | |
Gene Type | protein-coding | GO ID | GO:0002237 | UniProtAcc | Q5EBM0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
129607 | CMPK2 | LZE24T | Human | Esophagus | ESCC | 1.47e-24 | 7.32e-01 | 0.0596 |
129607 | CMPK2 | P2T-E | Human | Esophagus | ESCC | 3.58e-28 | 5.94e-01 | 0.1177 |
129607 | CMPK2 | P5T-E | Human | Esophagus | ESCC | 1.78e-03 | 1.23e-01 | 0.1327 |
129607 | CMPK2 | P8T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.31e-01 | 0.0889 |
129607 | CMPK2 | P9T-E | Human | Esophagus | ESCC | 3.67e-14 | 3.20e-01 | 0.1131 |
129607 | CMPK2 | P11T-E | Human | Esophagus | ESCC | 6.74e-09 | 3.63e-01 | 0.1426 |
129607 | CMPK2 | P17T-E | Human | Esophagus | ESCC | 1.49e-02 | 1.90e-01 | 0.1278 |
129607 | CMPK2 | P20T-E | Human | Esophagus | ESCC | 2.18e-03 | 2.08e-01 | 0.1124 |
129607 | CMPK2 | P21T-E | Human | Esophagus | ESCC | 1.96e-05 | 2.65e-01 | 0.1617 |
129607 | CMPK2 | P22T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.15e-01 | 0.1236 |
129607 | CMPK2 | P23T-E | Human | Esophagus | ESCC | 6.93e-10 | 3.82e-01 | 0.108 |
129607 | CMPK2 | P24T-E | Human | Esophagus | ESCC | 1.35e-23 | 5.43e-01 | 0.1287 |
129607 | CMPK2 | P27T-E | Human | Esophagus | ESCC | 4.31e-06 | 1.54e-01 | 0.1055 |
129607 | CMPK2 | P28T-E | Human | Esophagus | ESCC | 8.08e-19 | 3.78e-01 | 0.1149 |
129607 | CMPK2 | P31T-E | Human | Esophagus | ESCC | 6.38e-31 | 6.69e-01 | 0.1251 |
129607 | CMPK2 | P36T-E | Human | Esophagus | ESCC | 1.47e-14 | 5.66e-01 | 0.1187 |
129607 | CMPK2 | P37T-E | Human | Esophagus | ESCC | 1.87e-02 | 9.24e-02 | 0.1371 |
129607 | CMPK2 | P39T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.20e-01 | 0.0894 |
129607 | CMPK2 | P40T-E | Human | Esophagus | ESCC | 6.29e-20 | 5.15e-01 | 0.109 |
129607 | CMPK2 | P42T-E | Human | Esophagus | ESCC | 3.05e-02 | 1.26e-01 | 0.1175 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00725272 | Oral cavity | OSCC | pyrimidine-containing compound metabolic process | 44/7305 | 82/18723 | 4.95e-03 | 1.94e-02 | 44 |
GO:00091331 | Oral cavity | OSCC | nucleoside diphosphate biosynthetic process | 8/7305 | 10/18723 | 1.03e-02 | 3.53e-02 | 8 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CMPK2 | deletion | Frame_Shift_Del | novel | c.770delT | p.Ile257ThrfsTer12 | p.I257Tfs*12 | Q5EBM0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
CMPK2 | SNV | Missense_Mutation | rs527462136 | c.1310C>T | p.Thr437Met | p.T437M | Q5EBM0 | protein_coding | tolerated(0.28) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CMPK2 | SNV | Missense_Mutation | rs751941297 | c.721G>A | p.Asp241Asn | p.D241N | Q5EBM0 | protein_coding | deleterious(0.02) | benign(0.328) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CMPK2 | SNV | Missense_Mutation | c.727N>C | p.Cys243Arg | p.C243R | Q5EBM0 | protein_coding | tolerated(0.23) | benign(0.196) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CMPK2 | SNV | Missense_Mutation | novel | c.1004N>A | p.Ser335Asn | p.S335N | Q5EBM0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CMPK2 | SNV | Missense_Mutation | c.1134N>A | p.Ser378Arg | p.S378R | Q5EBM0 | protein_coding | deleterious(0.03) | possibly_damaging(0.643) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CMPK2 | SNV | Missense_Mutation | c.911N>T | p.Arg304Ile | p.R304I | Q5EBM0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CMPK2 | SNV | Missense_Mutation | novel | c.879N>T | p.Lys293Asn | p.K293N | Q5EBM0 | protein_coding | tolerated(0.1) | benign(0.039) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CMPK2 | SNV | Missense_Mutation | c.1111C>A | p.Leu371Ile | p.L371I | Q5EBM0 | protein_coding | tolerated(0.11) | benign(0.103) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CMPK2 | SNV | Missense_Mutation | c.692C>A | p.Pro231His | p.P231H | Q5EBM0 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |